Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,853 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial).
Misawa K, Mochizuki Y, Sakai M, Teramoto H, Morimoto D, Nakayama H, Tanaka N, Matsui T, Ito Y, Ito S, Tanaka K, Uemura K, Morita S, Kodera Y; Chubu Clinical Oncology Group. Misawa K, et al. Among authors: uemura k. Br J Surg. 2019 Nov;106(12):1602-1610. doi: 10.1002/bjs.11303. Epub 2019 Oct 1. Br J Surg. 2019. PMID: 31573086 Clinical Trial.
Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study.
Watanabe K, Yoh K, Hosomi Y, Usui K, Naka G, Kishi K, Uemura K, Ohashi Y, Kunitoh H. Watanabe K, et al. Among authors: uemura k. BMJ Open. 2022 Jan 4;12(1):e046451. doi: 10.1136/bmjopen-2020-046451. BMJ Open. 2022. PMID: 34983748 Free PMC article.
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).
Asao T, Shukuya T, Uemura K, Kitadai R, Yamamoto G, Mouri A, Tamaoka M, Imai R, Tsukita Y, Isobe K, Watanabe S, Kamimura M, Morita R, Kudo K, Inomata M, Tateishi K, Kakinuma K, Yoshioka H, Namba Y, Sumiyoshi I, Nakagawa T, Watanabe K, Kobayashi K, Takahashi K. Asao T, et al. Among authors: uemura k. Lung Cancer. 2024 Aug;194:107894. doi: 10.1016/j.lungcan.2024.107894. Epub 2024 Jul 14. Lung Cancer. 2024. PMID: 39029359
Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
Karayama M, Suda T, Yoh K, Usui K, Hosomi Y, Kishi K, Naka G, Watanabe K, Tamano S, Uemura K, Kunitoh H. Karayama M, et al. Among authors: uemura k. Lung Cancer. 2024 Dec;198:108037. doi: 10.1016/j.lungcan.2024.108037. Epub 2024 Nov 26. Lung Cancer. 2024. PMID: 39602849
Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
Okuno M, Ishii T, Ichida A, Soyama A, Takemura N, Hirono S, Eguchi S, Hasegawa K, Sasaki Y, Uemura K, Kokudo N, Hatano E. Okuno M, et al. Among authors: uemura k. BMC Cancer. 2023 Aug 21;23(1):780. doi: 10.1186/s12885-023-11302-6. BMC Cancer. 2023. PMID: 37605169 Free PMC article.
1,853 results